Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.
301-352-3042
Targeting the Apoptotic Pathway in Chondrosarcoma Using,Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual,Proapoptotic Receptor (DR4/DR5) Agonist